Drug Comparison
Liraglutide vs CagriSema: Complete Comparison
Liraglutide and CagriSema are both prescribed for metabolic health, but they work differently and deliver different outcomes in clinical trials. This comparison draws on head-to-head trial data where available and parallel trial comparisons where not.
⚠️ Medical Disclaimer
This page is for educational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs. Discuss all treatment decisions with a licensed healthcare provider who knows your complete medical history. Individual results vary significantly from clinical trial averages.
Weight Loss
CagriSema
22.7% vs 8.0%
Lower Cash Cost
Liraglutide
$1,349/mo vs $9,999/mo
Dosing
Liraglutide
Daily vs Weekly
FDA Status
Approved 2014
Phase 3
Side-by-Side Comparison Table
| Feature | Liraglutide | CagriSema |
|---|---|---|
| Brand Name(s) | Victoza, Saxenda | Cagrilintide + Semaglutide (combination) |
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonist + Amylin analog (cagrilintide) |
| FDA Status | Approved 2014 | Phase 3 |
| Mean Weight Loss | 8.0% (SCALE) | 22.7% (REDEFINE-1) |
| Starting Dose | 0.6 mg | 0.25 mg |
| Max Dose | 3.0 mg | 2.4 mg |
| Frequency | Daily | Weekly |
| Half-Life | 13 hrs | 168 hrs |
| Cash Price/Month | $1349 | N/A (investigational) |
| Prior Auth Required | Yes | No |
| Key Pivotal Trial | SCALE | REDEFINE-1 |
Weight Loss Efficacy: Liraglutide vs CagriSema
In their respective pivotal trials, Liraglutide achieved a mean weight loss of 8.0% (SCALE) while CagriSema achieved 22.7% (REDEFINE-1). This 14.7 percentage point difference represents a clinically meaningful gap, though direct head-to-head trial data between these specific agents may be limited.
Important caveat: These trials enrolled different populations (different BMI criteria, T2D vs non-diabetic, different geographies) and used different primary endpoints. Direct comparisons should be interpreted with caution.
Mechanism: How They Work Differently
Liraglutide is a GLP-1 receptor agonist. CagriSema is a GLP-1 receptor agonist + Amylin analog (cagrilintide). Both medications work through the GLP-1 pathway but differ in their additional receptor targets, half-lives, and molecular structures.
Side Effects
Both Liraglutide and CagriSema share a similar GI side effect profile. Common side effects for both include: constipation, diarrhea, fatigue, headache. These are typically most pronounced during dose escalation and improve with time.
Liraglutide-specific: Profile largely overlaps.. CagriSema-specific: Profile largely overlaps.
Cost Comparison
Cash pay prices vary significantly: Liraglutide lists at approximately $1349/month vs CagriSema at N/A (not commercially available). Both require prior authorization through most commercial insurers.
Which Is Right for You? Decision Guide
Consider Liraglutide if:
- ✓ Your insurance specifically covers Victoza
- ✓ Your prescriber has experience with Liraglutide
- ✓ You prefer daily injections for dose flexibility
- ✓ You have prior experience with GLP-1 receptor agonist agonists
Consider CagriSema if:
- ✓ Your insurance specifically covers Cagrilintide + Semaglutide (combination)
- ✓ Higher weight loss efficacy is your primary goal
- ✓ Once-weekly injection is preferred
- ✓ Simpler GLP-1 only mechanism is preferred
Bottom line: The choice between Liraglutide and CagriSema is best made with your prescribing clinician, accounting for your specific medical history, insurance coverage, prior treatment response, and metabolic goals. Neither medication is universally superior for all patients.